Advantages of liposomal delivery systems for anthracyclines.

Liposomes, closed vesicular structures consisting of one or more lipid bilayers, have generated a great deal of interest as drug delivery vehicles. In particular, they have been investigated for their ability to improve the delivery of chemotherapeutic agents to tumors, in efforts to increase therapeutic efficacy and decrease toxicity to normal cells. Development of liposomal chemotherapeutic agents has, in the past, been hindered primarily by the rapid uptake of liposomes by the reticuloendothelial system. Numerous strategies that seek to either exploit or avoid this phenomenon have been used. As a result, several liposomal chemotherapeutic agents are now available in the clinic. STEALTH, a novel liposomal system coated with polyethylene glycol, avoids uptake by the reticuloendothelial system, thus improving drug delivery to the tumor while decreasing toxicity. In pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), this delivery system encapsulates doxorubicin within polyethylene glycol-coated liposomes, leading to promising new applications for a well-established drug. Liposome-encapsulated doxorubicin citrate complex (Myocet [NPLD]), another liposomal delivery system for doxorubicin, lacks the polyethylene glycol coating, resulting in much shorter circulation times than those of PLD. Daunorubicin citrate liposome (DaunoXome [DNX]) contains daunorubicin encapsulated in a smaller liposome of a different lipid composition. It has circulation times between those of PLD and NPLD. This article reviews the advantages of liposomal delivery systems in general and the divergent approaches that have been taken in developing these agents.

[1]  D. Papahadjopoulos,et al.  Medical applications of liposomes , 1998 .

[2]  D. Lasič,et al.  Liposomes: From Physics to Applications , 1993 .

[3]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[4]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[5]  M. Newman,et al.  Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®) , 1994 .

[6]  M. Bally,et al.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. , 1986, Biochimica et biophysica acta.

[7]  W. Oyen,et al.  Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  D. Alberts,et al.  A Safety Review of Pegylated Liposomal Doxorubicin in the Treatment of Various Malignancies , 1997 .

[9]  P. Volberding,et al.  Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.

[10]  F. Torti,et al.  The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  N. Damjanov,et al.  Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. , 2001, Oncology.

[12]  G Blume,et al.  Liposomes for the sustained drug release in vivo. , 1990, Biochimica et biophysica acta.

[13]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[14]  A. Bangham,et al.  NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE. , 1964, Journal of molecular biology.

[15]  G. Storm,et al.  Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. , 1992, Biochimica et biophysica acta.

[16]  D. Friend,et al.  Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.

[17]  V. Torchilin Polymer-coated long-circulating microparticulate pharmaceuticals. , 1998, Journal of microencapsulation.

[18]  M. Somerfield,et al.  American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Abrams Rm,et al.  Liposome disposition in vivo: effects of pre-dosing with lipsomes. , 1980 .

[20]  M. Newman,et al.  Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. , 1999, The Journal of pharmacology and experimental therapeutics.

[21]  O. Boerman,et al.  Liposomes for scintigraphic detection of infection and inflammation. , 1999, Advanced drug delivery reviews.

[22]  Y. Yarden,et al.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.

[23]  T. Allen The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system , 1994 .

[24]  M. Ostro Liposomes : from biophysics to therapeutics , 1987 .

[25]  G. H. Coombs,et al.  Vesicular Systems (Niosomes and Liposomes) for Delivery of Sodium Stibogluconate in Experimental Murine Visceral Leishmaniasis , 1988, The Journal of pharmacy and pharmacology.

[26]  G. Batist,et al.  Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy , 2002, Expert opinion on pharmacotherapy.

[27]  K. Gelmon,et al.  Phase I study of liposomal vincristine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Ahmad,et al.  Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. , 2001, Anticancer research.

[29]  Kshirsagar Drug delivery systems , 2000 .

[30]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  C. Hunt,et al.  Liposome disposition in vivo. III. Dose and vesicle-size effects. , 1981, Biochimica et biophysica acta.

[32]  P. Working,et al.  Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts , 1994, Cancer.

[33]  P. Cullis,et al.  Ganglioside GM1 and Hydrophilic Polymers Increase Liposome Circulation Times by Inhibiting the Association of Blood Proteins , 1992 .

[34]  B. Conley,et al.  Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin , 2004, Cancer Chemotherapy and Pharmacology.

[35]  I. Fidler,et al.  Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. , 1998, Pharmacology & therapeutics.

[36]  T. Allen,et al.  Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. , 1996, Journal of pharmaceutical sciences.

[37]  W. Oyen,et al.  99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  Y. Barenholz,et al.  Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. , 1989, European journal of cancer & clinical oncology.

[39]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Schiffelers,et al.  Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating. , 2000, Biochimica et biophysica acta.

[41]  Aquilur Rahman,et al.  A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. , 1989, American journal of obstetrics and gynecology.

[42]  T. Allen Toxicity of drug carriers to the mononuclear phagocyte system , 1988 .

[43]  M. Woodle,et al.  Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[44]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[45]  M. Bally,et al.  Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. , 1985, Biochimica et biophysica acta.

[46]  T. Allen,et al.  Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. , 1983, The Journal of pharmacology and experimental therapeutics.

[47]  M. Ercan,et al.  Radiopharmaceuticals for the visualization of infectious and inflammatory lesions. , 2000, Current pharmaceutical design.

[48]  T. Ishida,et al.  A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs , 1999, FEBS letters.

[49]  G. Lopez-Berestein,et al.  The past, present, and future uses of liposomes in treating infectious diseases. , 1995, Immunopharmacology and immunotoxicology.

[50]  N. Petrelli,et al.  Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). , 1993, Cancer research.

[51]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[52]  M. Newman,et al.  Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs , 1999, Human & experimental toxicology.

[53]  S M Gruner,et al.  Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. , 1998, Biochimica et biophysica acta.

[54]  W. Alvord,et al.  A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[56]  F. Martin,et al.  Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. , 2004, Seminars in oncology.

[57]  R. Janknegt Liposomal formulations of cytotoxic drugs , 1996, Supportive Care in Cancer.

[58]  Y. Barenholz,et al.  In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. , 1992, Biochimica et biophysica acta.

[59]  D. Ribatti,et al.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.

[60]  G. Poste Liposome targeting in vivo: Problems and opportunities , 1983 .

[61]  L. Blumenson,et al.  Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. , 1998, Gynecologic oncology.

[62]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[63]  A. Gabizon,et al.  Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. , 1991, Biochimica et biophysica acta.

[64]  C. Presant,et al.  Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. , 1983, Science.

[65]  T M Allen,et al.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.

[66]  E. Moase,et al.  Therapeutic opportunities for targeted liposomal drug delivery , 1996 .

[67]  C. McLaren,et al.  Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. , 2002, Gynecologic oncology.

[68]  M. Newman,et al.  Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants , 1995, Antimicrobial agents and chemotherapy.

[69]  R. Schiffelers,et al.  Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat Klebsiella pneumoniae Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin , 2001, Antimicrobial Agents and Chemotherapy.

[70]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[71]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  H. Groen,et al.  Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  T. Ishida,et al.  Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. , 2001, Biochimica et biophysica acta.

[74]  Y. Barenholz,et al.  The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. , 1990, Biochimica et biophysica acta.

[75]  T M Allen,et al.  Large unilamellar liposomes with low uptake into the reticuloendothelial system , 1987, FEBS letters.

[76]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[77]  K. Gelmon,et al.  Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection , 1998, Cancer Chemotherapy and Pharmacology.

[78]  T. Allen,et al.  Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. , 1989, Biochimica et biophysica acta.

[79]  B. Calabretta,et al.  Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. , 2000, Journal of the National Cancer Institute.

[80]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[81]  W. Oyen,et al.  Technetium-99m-labeled liposomes to image experimental colitis in rabbits: comparison with technetium-99m-HMPAO-granulocytes and technetium-99m-HYNIC-IgG. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[82]  A. Janoff,et al.  CHAPTER 8.3 – The Liposome Company: Lipid-based pharmaceuticals in clinical development , 1998 .

[83]  I. Ahmad,et al.  Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. , 1993, Cancer research.

[84]  D. Stuart,et al.  A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1 , 2000, Cancer Gene Therapy.

[85]  C. Shapiro,et al.  Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[87]  F. Martin Pegylated Liposomal Doxorubicin: Scientific Rationale and Preclinical Pharmacology , 1997 .

[88]  D. Northfelt,et al.  Population pharmacokinetics and pharmacodynamics of pegylated‐liposomal doxorubicin in patients with AIDS‐related Kaposi's sarcoma , 1997, Clinical pharmacology and therapeutics.

[89]  K. Harrington,et al.  The Biodistribution and Pharmacokinetics of Stealth Liposomes in Patients with Solid Tumors , 1997 .

[90]  P. Caliceti,et al.  New synthetic amphiphilic polymers for steric protection of liposomes in vivo. , 1995, Journal of pharmaceutical sciences.

[91]  M. Bally,et al.  Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. , 2000, Cancer research.

[92]  Tavassoli Fa,et al.  A Comparison of Two Commercially Available in vitro Chemosensitivity Assays , 1995 .